We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 135

When is There Standing to Appeal a PGR Final Written Decision?
  • Marshall Gerstein & Borun LLP
  • USA
  • July 5 2018

In Altaire Pharm., Inc. v. Paragon Biotek, Inc., Case No. 2017-1487 (Fed. Cir. May 2, 2018), the Federal Circuit reversed in part a PGR final written


Federal Circuit Affirms Tygacil Formulation Patent
  • Foley & Lardner LLP
  • USA
  • August 23 2016

In Apotex, Inc. v. Wyeth LLC, the Federal Circuit affirmed the decision of the USPTO Patent Trial and Appeal Board (PTAB) finding that Apotex had


FC Denies Data Protection for Ester of a Previously Approved Medicinal Ingredient
  • PCK Perry + Currier Inc Currier + Kao LLP
  • Canada
  • August 2 2016

This Federal Court (“FC”) decision reflects the Minister of Health’s (“Minister”) continued trend in applying a restrictive interpretation in


FTC Requires Divestitures in Generic Pharmaceutical Markets Even Though the Target Had Exited the Markets
  • Weil Gotshal & Manges LLP
  • USA
  • March 7 2016

On February 19, 2016, the Federal Trade Commission (“FTC”) announced a proposed consent agreement with Hikma Pharmaceuticals PLC (“Hikma”) to settle


Purdue OxyContin Patents Invalid Despite Stemming From Discovery Of Source Of Toxic Impurity
  • Foley & Lardner LLP
  • USA
  • February 2 2016

In Purdue Pharma L.P. v. Epic Pharma LLC, the Federal Circuit affirmed the district court decision holding four OxyContin patents invalid as obvious


Pharma in brief - Federal Court of Appeal refuses to reweigh evidence from a prohibition application under the PM(NOC) Regulations
  • Norton Rose Fulbright
  • Canada
  • October 6 2015

In two decisions relating to VIGAMOX (moxifloxacin hydrochloride), the Federal Court of Appeal held that it is not the role of an appellate court to


Pharma in brief - no induced infringement: patent struck from application under s. 6(5)(b) of the PM(NOC) Regulations
  • Norton Rose Fulbright
  • Canada
  • April 16 2015

Prothonotary Lafrenière issued an order pursuant to section 6(5)(b) of the PM(NOC) Regulations striking all allegations relating to one of


Public interest groups sue FDA over animal drug approvals
  • Shook Hardy & Bacon LLP
  • USA
  • November 7 2014

The Center for Food Safety and two other public interest organizations have filed a lawsuit against the U.S. Food and Drug Administration (FDA)


Novartis continues its successful injunction spree
  • Lakshmikumaran & Sridharan
  • India
  • September 24 2014

Novartis AG holds the patent for the drug containing the active pharmaceutical ingredients vildagliptin and vildagliptin in combination with


Withdrawal of bupropion hydrochloride extended-release 300 mg by Watson
  • Haug Partners LLP
  • USA
  • October 16 2013

Based on data submitted by Watson Pharmaceuticals Inc. ("Watson") (recently merged with Actavis Inc. ("Actavis")), FDA announced last week that